The FDA has approved Mustang Bio’s (NASDAQ:MBIO) IND application to initiate a multi-center Phase 1/2 clinical trial of MB-102 (CD123 CAR T) in acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm and high-risk myelodysplastic syndrome.
MB-102 is a CAR T cell therapy that is produced by engineering patient T cells to recognize and eliminate CD123-expressing tumors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.